SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3027Incyte Corporation ( INCY) and MedImmune, the global biologics research and devenigel bates-5/14/2014
3026ditto, HER2-negative breast.... clinicaltrials.gov Be interesting to see if GIscaram(o)uche-4/23/2014
3025>> And it _is_ rux's rolling rock, rather than 110's or 986's scaram(o)uche-4/23/2014
3024As everyone here probably knows, title abstracts (minus late breakers) are out fscaram(o)uche-4/22/2014
3023>> Gilead isn't letting cyt-387 moss grow under rux's rolling rockscaram(o)uche-4/21/2014
3022#2 was first from this Zach guy, who is quite good, a week ago. So, my news is scaram(o)uche-4/9/2014
3021Hey! Hope everyone is well/thriving! >> Not sure where I'd buy back scaram(o)uche-4/9/2014
3020Top line results of ruxolitinib in PV; hits primary endpoint in P3: >>Martuck-4/8/2014
3019On the INCY competition front... "Galapagos NV ( GLPGF) announced today thBiotech Jim-2/28/2014
3018Probably a coincidence. Musings on MRK's MK-3475 deals announced today: siDewDiligence_on_SI-2/5/2014
3017Noticed a concomitant movement of the release of this news and the dive of the sD.Lu-2/5/2014
3016From Practice Update, an oncology journal updater that I subscribe to. The NatuBiotech Jim-1/28/2014
3015Does anyone have any thoughts, input or info on the Ruxo Phase 2 PanCa subgroup,quantman-1/16/2014
3014<Any speculation why Friedman resigned? He did present at JP Morgan.> LooBiotech Jim-1/14/2014
3013Incyte announces the appointment of former Novartis Oncology president HervéD.Lu-1/14/2014
3012Paul Friedman will present at JP Morgan Healthcare Conference on Monday, Jan 13D.Lu-1/2/2014
3011>> a 093 plus ruxolitinib combo, lymphoma, seemed like a telegraphed next-scaram(o)uche-12/23/2013
3010Fast, indeed, at 3 months. I gather that is as mature as their data gets at thituck-12/10/2013
3009First, thanks for pointing me to that poster/graphic. Hadn't seen it, only scaram(o)uche-12/10/2013
3008OK, thanks, but look at my edit. I gather you already found the Incyte results tuck-12/10/2013
3007>> Geron's results don't seem to beat that << Yes, they do.scaram(o)uche-12/10/2013
3006"An exploratory analysis of data collected over five years in the ongoing tuck-12/10/2013
300518% reversal of marrow fibrosis, damn good but not as good as some expect/hope. scaram(o)uche-12/9/2013
3004finance.yahoo.com Jakafi® (ruxolitinib) Continues to Show Improved Overallscaram(o)uche-12/9/2013
3003>> early efficacy, panobinostat combo, to the presented at meeting <<scaram(o)uche-12/9/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News